The company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies.

Agenus' leading fully-owned candidates are zalifrelimab and balstilimab, which have both reached Phase II stage.